Ryotaro Igusa
Ryotaro Igusa has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiro Sakamoto
Department of Pathology, Osaki Citizen Hospital, Osaki 989-6183, Japan
2 shared publications - Masakazu Ichinose
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
2 shared publications - Taizou Hirano
Department of Occupational Health, Tohoku University Graduate School of Medicine, Japan
2 shared publications - Toshiaki Kikuchi
Department of Respiratory Medicine and Infectious Diseases Niigata University Graduate School of Medical and Dental Sciences Niigata Japan
2 shared publications - Akira Inoue
Tohoku University Hospital, Sendai, Japan
1 shared publication - Akira Inoue
Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan
1 shared publication
Latest Publications
- Open Access
- 10 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2501
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.
- 10 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2501
Open AccessA Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.
- 14 July 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (6) , 494-499
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review
- 14 July 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (6) , 494-499
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review
- 1 May 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (3) , 211-215
Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review
- 1 May 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (3) , 211-215
Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review
- Open Access
- 1 January 2013
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 52 (24) , 2789-2793
Two Cases of Acute Respiratory Distress Syndrome with High Values of Chlamydophila pneumoniae-Specific Antibodies
We herein report two cases of acute respiratory distress syndrome (ARDS) with high values of Chlamydophila pneumoniae-specific antibodies. In the first case (a 65-year-old man), high levels of anti-C. pneumoniae antibodies (IgG and IgA) were detected on admission, and the anti-C. pneumoniae IgA level rose by Day 30. The patient was successfully treated with quinolone and steroids. In the second case (an 85-year-old man), abnormally high levels of anti-C. pneumoniae IgM were detected on admission. The patient did not recover, despite receiving treatment with several antibiotics and anti-inflammatory agents. Neither of the patients displayed other pathogen-specific antigens or antibodies. Chlamydophila pneumonia is usually mild, although it can cause severe interstitial pneumonia and ARDS in reinfected patients and the elderly.
- 1 January 2013
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 52 (24) , 2789-2793
Open AccessTwo Cases of Acute Respiratory Distress Syndrome with High Values of Chlamydophila pneumoniae-Specific Antibodies
We herein report two cases of acute respiratory distress syndrome (ARDS) with high values of Chlamydophila pneumoniae-specific antibodies. In the first case (a 65-year-old man), high levels of anti-C. pneumoniae antibodies (IgG and IgA) were detected on admission, and the anti-C. pneumoniae IgA level rose by Day 30. The patient was successfully treated with quinolone and steroids. In the second case (an 85-year-old man), abnormally high levels of anti-C. pneumoniae IgM were detected on admission. The patient did not recover, despite receiving treatment with several antibiotics and anti-inflammatory agents. Neither of the patients displayed other pathogen-specific antigens or antibodies. Chlamydophila pneumonia is usually mild, although it can cause severe interstitial pneumonia and ARDS in reinfected patients and the elderly.